

## THE UNITED STATES OF AMERICA

TO AND TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 03, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/523,942

FILING DATE: November 21, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/38950



Certified By



Jon W Dudas

Under Secretary  
of Commerce for Intellectual Property  
and Acting Director of the  
United States Patent and Trademark Office

BEST AVAILABLE COPY

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**  
 This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR §1.53(c).

U.S. PTO  
60/523942

1121/03

<b>INVENTOR(S)</b>				
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)		
Ashok Rifat Evelyn A. Robert W.	Saluja Sharif Kurt-Jones Finberg	Framingham, MA Worcester, MA Belmont, MA Sudbury, MA		
Additional inventors are being named on the <u>0</u> separately numbered sheets attached hereto				
<b>TITLE OF THE INVENTION (500 characters max)</b>				
<b>PANCREATITIS</b>				
<b>CORRESPONDENCE ADDRESS</b>				
Direct all correspondence to:				
<input checked="" type="checkbox"/> Customer Number: <b>26161</b>				
<b>OR</b>				
<input type="checkbox"/> Firm or Individual Name				
Address				
Address				
City	State	ZIP		
Country	United States	Telephone	Fax	
<b>ENCLOSED APPLICATION PARTS (check all that apply)</b>				
<input checked="" type="checkbox"/> Specification	Number of Pages	20	<input type="checkbox"/> CD(s), Number	
<input checked="" type="checkbox"/> Drawing(s)	Number of Sheets	4	<input type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76.				
<b>METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT</b>				
<input checked="" type="checkbox"/> Applicant Claims small entity status. See 37 CFR 1.27. <input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees. <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <b>06-1050</b> <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.			FILING FEE AMOUNT (\$)	<b>\$80</b>
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. <input checked="" type="checkbox"/> No. <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:				

Respectfully submitted,

Signature Date November 21, 2003Typed Name Janice L. Kugler, Reg. No. 50,429Telephone No. (617) 542-5070Docket No. 07917-251P01

20760854.doc

**CERTIFICATE OF MAILING BY EXPRESS MAIL**Express Mail Label No. EV330510093USDate of Deposit November 21, 2003

**PROVISIONAL APPLICATION FOR PATENT**

under

**37 CFR §1.53(c)**

**TITLE:** **PANCREATITIS**

**APPLICANT:** **ASHOK SALUJA, RIFAT SHARIF,  
EVELYN A. KURT-JONES AND ROBERT W. FINBERG**

**CERTIFICATE OF MAILING BY EXPRESS MAIL**

Express Mail Label No. EV330510093US

November 21, 2003  
Date of Deposit

## PANCREATITIS

### **FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT**

This invention was made with Government support under Grant No. DK58694 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention.

### **BACKGROUND**

5        Acute pancreatitis is a multi-faceted disease that is associated with considerable morbidity and mortality. In the United States alone, more than 300,000 patients are hospitalized annually with pancreatitis. Lung, kidney, and heart failure may all occur in severe cases. Pancreatitis is a primary factor in about 3,200 deaths, and a contributing factor in about 4,000 additional deaths, annually. Direct costs attributable to pancreatitis top \$2 billion annually. See, 10 e.g., Saluja and Bhagat, *Gastroenterology*, 124(3):844-847 (2003).

15       Conventional wisdom states that pancreatitis begins with the intra-pancreatic activation of digestive enzyme zymogens, acinar cell injury, and activation of transcription factors such as Nuclear Factor Kappa B (NF- $\kappa$ B) and Activator Protein-1 (AP-1). This is followed by a proinflammatory cascade leading to acinar cell necrosis, systemic inflammatory response syndrome (SIRS) and distant organ dysfunction including lung injury that frequently manifests as the acute respiratory distress syndrome (ARDS). Ultimately, the severity of acute pancreatitis depends upon the extent of systemic inflammatory responses.

20       The Toll-Like Receptors, or "TLRs," are named for their structural and functional homology to a receptor found in the *Drosophila* fruit fly, named TOLL. In humans, TLRs play an important role in activating an innate immune response to pathogen-related molecules, and hence are also known as pattern recognition receptors (PRR's). Over ten members of the TLR family have been identified in the human and mouse, designated as TLR2, TLR4, TLR5, and so on, each receptor recognizing a small range of conserved molecules from a group of pathogens. 25 TLRs are expressed on monocytes, macrophages, dendritic cells, lymphocytes and in other cell lines, including vascular endothelial cells, lung and intestinal epithelial cells, cardiac myocytes, and adipocytes.

      TLR4 is perhaps the best characterized member of this family of receptors. It binds to lipopolysaccharide (LPS) as well as number of host protein molecules that are released at sites of

damage and infection. TLR4 is a type I transmembrane protein with extracellular domains containing leucine-rich repeats that may participate in ligand recognition. The intracellular domains contain regions that are highly homologous to the intracellular domain of the IL-1R, and these regions are referred to as Toll/IL-1R (TIR) domains. The intracellular signaling pathway is known to activate mainly the NF- $\kappa$ B transcription factor, which, in turn, triggers the expression of many pro-inflammatory cytokines such as TNF-alpha, IL-1beta, IL-6, and IL-8, and leads to maturation of antigen-presenting cells.

## SUMMARY

The present invention is based, in part, on the discovery that the TOLL-Like Receptor 4 (TLR4) plays a role in the development of pancreatitis, and is therefore a target for the development of therapeutic compounds for the treatment of pancreatitis. Thus, the invention includes methods of screening for compounds that target TLR4 that are useful in the treatment of pancreatitis and pancreatitis-associated disorders such as pancreatitis-associated lung injury, heart failure, and kidney failure.

In one aspect, the new methods described herein include methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis. The methods include providing a cell expressing a TLR4 protein; contacting the cell with a test compound; and evaluating an effect of the test compound on the activity of the TLR4 protein. A test compound that reduces the activity of the TLR4 protein is a candidate therapeutic agent for use in the treatment of acute pancreatitis, and can be selected for further evaluation, e.g., in an animal model of pancreatitis.

The test compound can be any organic or inorganic compound, including small organic or inorganic molecules, biopolymers such as nucleic acids, e.g., siRNAs or antisense nucleic acids; polypeptides such as peptides and TLR4 specific antibodies; and hybrid molecules such as ribozymes.

The test compound can reduce the activity of the TLR4 protein in a number of ways, e.g., (i) by reducing the level (number) of TLR4 proteins, i.e., by reducing the transcription of TLR4 mRNA or the half-life of TLR4 mRNA, or by reducing the translation of TLR4 protein, trafficking of TLR4 protein, half-life of TLR4 protein, or cellular localization of TLR4 protein; (ii) by reducing the activity of the TLR4 protein by interfering with binding of TLR4 to a TLR4

binding partner, e.g., Tollip, MyD88, TIRAP/MAL, MD-2, CD14, and IRAK, or by altering one or more post-translational modifications.

In another aspect, the methods described herein include methods for identifying candidate therapeutic agents for use in the treatment of acute pancreatitis. The methods typically include 5 selecting a test compound identified by a method described herein as a candidate therapeutic agent; providing a model system for acute pancreatitis (e.g., an animal model, such as is known in the art and described herein); contacting the model system with the test compound; and evaluating a clinical parameter relating to the acute pancreatitis in the model system in the presence and the absence of the test compound. An improvement in the clinical parameter 10 indicates that the test compound is a candidate therapeutic agent for use in the treatment of acute pancreatitis.

In another aspect, the new methods described herein include additional methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis. The methods include providing a test compound that is known or suspected to decrease TLR4 15 activity; providing a model system for acute pancreatitis; contacting the model system with the test compound; and evaluating a clinical parameter relating to the acute pancreatitis in the model system in the presence and the absence of the test compound. An improvement in the clinical parameter indicates that the test compound is a candidate therapeutic agent for use in the treatment of acute pancreatitis.

20 Suitable model systems for acute pancreatitis for use in the methods described herein include animal models of acute pancreatitis, and patients diagnosed with acute pancreatitis.

In some embodiments, the parameter relating to the acute pancreatitis is evaluated by direct clinical observation, e.g., time of onset, severity, duration, or recurrence of the pancreatitis, or the occurrence, time of onset, severity, duration, or recurrence of a pancreatitis-associated 25 disorder such as injury to one or more organ systems in the model system, e.g., lung injury, or kidney or heart failure. In some embodiments, the parameter is measured by measuring MPO activity, serum amylase levels, percent necrosis, or percent edema in the pancreas of the animal model.

30 In a further aspect, the methods described herein include a method of treating a patient (e.g., a human or veterinary patient or an experimental animal) having acute pancreatitis, by administering to the patient a therapeutically effective amount of a candidate therapeutic agent

identified by a method described herein. In some embodiments the patient also has a pancreatitis-associated disorder selected from the group consisting of lung injury, kidney failure, and heart failure, and the candidate agent also treats the associated disorder.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

#### DESCRIPTION OF DRAWINGS

FIG 1 is a bar graph illustrating the levels of serum amylase in TLR2 knockout (TLR2), TLR4 knockout (TLR4), and wild type (W/T) mice after twelve caerulein injections i.p. (CER).

FIG 2 is a bar graph illustrating MPO activity in TLR2 knockout (TLR2), TLR4 knockout (TLR4), and wild type (W/T) mice after twelve caerulein injections i.p. (CER).

FIG 3 is a bar graph illustrating the percent edema in the pancreas of TLR2 knockout (TLR2), TLR4 knockout (TLR4), and wild type (W/T) mice after twelve caerulein injections i.p. (CER).

FIG. 4 is a bar graph illustrating the percent necrosis in the pancreas of TLR2 knockout (TLR2), TLR4 knockout (TLR4), and wild type (W/T) mice after twelve caerulein injections i.p. (CER).

FIG 5 is a photomicrograph of section of pancreatic tissue from a wild type control (untreated) mouse, stained with hematoxylin/eosin.

FIG 6 is a photomicrograph of section of pancreatic tissue from a wild type control mouse after 12 injections of caerulein, stained with hematoxylin/eosin.

FIG 7 is a photomicrograph of section of pancreatic tissue from a TLR4 knockout control (untreated) mouse, stained with hematoxylin/eosin.

FIG. 8 is a photomicrograph of section of pancreatic tissue from a TLR4 knockout control mouse after 12 injections of caerulein, stained with hematoxylin/eosin.

#### DETAILED DESCRIPTION

The present invention is based, in part, on the discovery that the deletion of TOLL-Like Receptor 4 (TLR4) in a knockout mouse results in significantly diminished severity of experimentally-induced pancreatitis. This is evidence that TLR4 plays a role in the development of pancreatitis, and is therefore a target for the development of therapeutic compounds for the treatment of pancreatitis.

The invention provides, *inter alia*, methods of screening test compounds for use as therapeutic agents to treat acute pancreatitis, and pancreatitis-associated disorders (e.g., pancreatitis-associated lung injury, heart failure, and/or kidney failure; see, e.g., Saluja and Steer, *Digestion* 60(suppl. 1) 27-33 (1999); Song et al., *Am. J. Physiol. Gastrointest. Liver Physiol.* 283:G1166-G1174 (2002); *Pancreatitis*, NIH Publication No. 03-1596, June 2003), in mammals, e.g., humans. The test compounds are evaluated for their ability to decrease the activity of TLR4, e.g., by reducing:

- (a) the level (number) of TLR4 proteins; e.g., by reducing the transcription of TLR4 mRNA or the half-life of TLR4 mRNA, or by reducing the translation or half-life of the TLR4 protein, or by altering trafficking or cellular localization of TLR4 protein;
- (b) the activity of the TLR4 protein directly by interfering with binding of TLR4 to a TLR4 binding partner, e.g., Tollip, MyD88, TIRAP/MAL, MD-2, CD14, and IRAK (see, e.g., Underhill and Ozinsky, *Curr. Op. Immunol.* 2002, 14:103-110, or Takeda et al., *Annu. Rev. Immunol.* 2003, 21:335-76.); and/or
- (c) the activity of the TLR4 protein by altering one or more post-translational modifications, or by altering trafficking or cellular localization of TLR4 protein.

#### Test Compounds/Candidate Therapeutic Agents

As described herein, the methods include evaluating test compounds for the ability to decrease the activity of TLR4, and, in some embodiments, further evaluating selected test compounds (e.g., candidate therapeutic agents) for use as therapeutic agents for the treatment of pancreatitis and pancreatitis-associated disorders. The test compound can be any compound,

e.g., a compound that is known to have, or suspected to have, an effect on TLR4 activity, e.g., a TLR4 antagonist, or a compound of known or unknown structure in a library of compounds. In some embodiments, for example, the test compound is a biopolymer such as a nucleic acid, e.g., an siRNA, ribozyme, or antisense nucleic acid that targets a TLR4 nucleic acid; or a peptide or polypeptide, e.g., a dominant negative form of TLR4, or a TLR4 specific antibody. In some 5 embodiments, the test compound is a small organic or inorganic molecule. In some embodiments, the test compound is subjected to one or more rounds of optimization.

#### Nucleic Acids

In some embodiments, the test compound comprises a nucleic acid, e.g., an siRNA, 10 antisense or ribozyme, that targets a TLR4 sequence, e.g., the human TLR4 sequence (genbank accession nos. U88880 and AH009665).

siRNA: RNAi is a remarkably efficient process whereby double-stranded RNA (dsRNA, also referred to herein as si RNAs or ds siRNAs, for double-stranded small interfering RNAs,) induces the sequence-specific degradation of homologous mRNA in animals and plant 15 cells (Hutvagner and Zamore, *Curr. Opin. Genet. Dev.*:12, 225-232 (2002); Sharp, *Genes Dev.*, 15:485-490 (2001)). In mammalian cells, RNAi can be triggered by 21-nucleotide (nt) duplexes of small interfering RNA (siRNA) (Chiu *et al.*, *Mol. Cell.* 10:549-561 (2002); Elbashir *et al.*, *Nature* 411:494-498 (2001)), or by micro-RNAs (miRNA), functional small-hairpin RNA (shRNA), or other dsRNAs which are expressed *in vivo* using DNA templates with RNA 20 polymerase III promoters (Zeng *et al.*, *Mol. Cell* 9:1327-1333 (2002); Paddison *et al.*, *Genes Dev.* 16:948-958 (2002); Lee *et al.*, *Nature Biotechnol.* 20:500-505 (2002); Paul *et al.*, *Nature Biotechnol.* 20:505-508 (2002); Tuschl, T., *Nature Biotechnol.* 20:440-448 (2002); Yu *et al.*, *Proc. Natl. Acad. Sci. USA* 99(9):6047-6052 (2002); McManus *et al.*, *RNA* 8:842-850 (2002); Sui *et al.*, *Proc. Natl. Acad. Sci. USA* 99(6):5515-5520 (2002).)

25 One of skill in the art would be able to design an siRNA to disrupt TLR4 gene expression by targeting TLR4 mRNA. Thus, the test compounds can include dsRNA molecules comprising 16-30, e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in 30 the mRNA, and the other strand is identical or substantially identical to the first strand. The dsRNA molecules can be chemically synthesized, or can be transcribed *in vitro* from a DNA

template, or *in vivo* from, e.g., shRNA. An siRNA test compound can be, e.g., a population of identical or mixed siRNAs. The siRNAs can be designed using any method known in the art, including a number of computer-based algorithms. A number of companies provide enhanced siRNAs, e.g., Dharmacon, Inc., Lafayette, CO. In some embodiments, the target TLR4 sequence 5 is the open reading frame of the sequence of human TLR4 (genbank accession no. U88880), and the siRNA is an siRNA selected from table 1. Start refers to the starting point of the siRNA in the target TLR4 sequence (genbank accession no. U88880).

Table 1: Exemplary siRNAs

siRNA SEQUENCE	SEQ ID NO:	Start	GC Content
GGCATTAGGCAGCTATAG	1	364	47.37 %
GCTATAGCTTCTCAGTT	2	376	36.84 %
GGTGTGAAATCCAGACAAT	3	424	42.11 %
GCCACCTCTTACCTTAAT	4	469	47.37 %
CCATTGAAGAATTCCGATT	5	1015	36.84 %
ATTCCGATTAGCATACTTA	6	1025	31.58 %
TTCCGATTAGCATACTTAG	7	1026	36.84 %
CTTAGACTACTACCTCGAT	8	1040	42.11 %
CTACTACCTCGATGATATT	9	1046	36.84 %
CTACCTCGATGATATTATT	10	1049	31.58 %
CCTCGATGATATTATTGAC	11	1052	36.84 %
TAATTCGGATGGCAACAT	12	1148	36.84 %
ATTCGGATGGCAACATT	13	1150	36.84 %
TTTCGGATGGCAACATT	14	1151	36.84 %
AGGCTTACTTCACTCCA	15	1227	42.11 %
CTCAGAAACCTCATTACC	16	1500	42.11 %
GAAACCTCATTACCTTGA	17	1504	36.84 %
AACCTCATTACCTTGACA	18	1506	36.84 %
TGGCTTGTCCAGTCTCGAA	19	1568	52.63 %
ACAGCATTAACTCACTCT	20	1704	36.84 %
TATGAGCCACAACAACCTC	21	1742	42.11 %
GTAGTCTAGCTTCTTAAA	22	1870	31.58 %
GTTTCCTGCAATGGATCAA	23	1930	42.11 %
ATGTGCAACACCTTCAGAT	24	1988	42.11 %
AAGTATGGTAGAGGGTAAA	25	2160	36.84 %
TGATGCCCTTGTATCTAC	26	2186	36.84 %
TGCCTTGTATCTACTCA	27	2189	36.84 %
AAAGCCGAAAGGTGATTGT	28	2350	42.11 %
AAGCCGAAAGGTGATTGTT	29	2351	42.11 %
AGCCGAAAGGTGATTGTTG	31	2352	47.37 %
GCCGCTGGTGTATCTTGA	31	2395	52.63 %
GCAGTCGTGCTGGTATCAT	32	2446	52.63 %
GTCGTGCTGGTATCATCTT	33	2449	47.37 %

Antisense: An "antisense" nucleic acid can include a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to a TLR4 mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand of a target sequence, or to only a portion thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding TLR4 (e.g., the 5' and 3' untranslated regions).

An antisense nucleic acid can be designed such that it is complementary to the entire coding region of a target TLR4 mRNA, but can also be an oligonucleotide that is antisense to only a portion of the coding or noncoding region of the target mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the target mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length. An antisense molecule can also be obtained commercially, e.g., using a commercial design and synthesis service such as that provided by Molecula Research Laboratories, LLC, Herndon, VA; such services can apply proprietary or other algorithms to determine the sequence of an antisense nucleic acid to target TLR4.

An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. The antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

Antisense nucleic acid molecules for use in the methods described herein can be administered to a subject (e.g., by direct injection at a tissue site), or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a TLR4 protein to

thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter can be used.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier *et al.*, Nucleic Acids. Res. 15:6625-6641 (1987)). The antisense nucleic acid molecule can also comprise a 2'- $\alpha$ -methylribonucleotide (Inoue *et al.* Nucleic Acids Res. 15:6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue *et al.* FEBS Lett., 215:327-330 (1987)).

TLR4 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of TLR4 (e.g., promoters and/or enhancers) to form triple helical structures that prevent transcription of the TLR4 gene in target cells. See generally, Helene, C. *Anticancer Drug Des.* 6:569-84 (1991); Helene, C. *Ann. N.Y. Acad. Sci.* 660:27-36 (1992); and Maher, *Bioassays* 14:807-15 (1992). The potential sequences that can be targeted for triple helix formation can be increased by creating a so called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

**Ribozymes:** Ribozymes are a type of RNA that can be engineered to enzymatically cleave and inactivate other RNA targets in a specific, sequence-dependent fashion. By cleaving the target RNA, ribozymes inhibit translation, thus preventing the expression of the target gene. Ribozymes can be chemically synthesized in the laboratory and structurally modified to increase their stability and catalytic activity using methods known in the art. Alternatively, ribozyme genes can be introduced into cells through gene-delivery mechanisms known in the art. A

ribozyme having specificity for a TLR4-encoding nucleic acid can include one or more sequences complementary to the nucleotide sequence of a TLR4 cDNA disclosed herein, and a sequence having known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246, or Haselhoff and Gerlach, *Nature* 334:585-591 (1988)). For example, a derivative of 5 a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a TLR4-encoding mRNA. See, e.g., Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, TLR4 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. *Science* 10 261:1411-1418 (1993). Additional guidance on the design of antisense oligodeoxynucleotide and ribozyme molecules can be found, e.g., in Probst, *Methods*. 22(3):271-81 (2000).

Polypeptides

TLR4 Antibodies: The test compound can be an antibody that is specific for TLR4. Such antibodies can include any TLR4-specific antibody (e.g., a monospecific, or a recombinant 15 or modified antibody), and include antigen-binding fragments thereof (e.g., Fab, F(ab')<sub>2</sub>, Fv or single chain Fv fragments). The antibodies can be of the various isotypes, including: IgG (e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, IgG<sub>4</sub>), IgM, IgA<sub>1</sub>, IgA<sub>2</sub>, IgD, or IgE. The antibody molecules can be full-length (e.g., an IgG<sub>1</sub> or IgG<sub>4</sub> antibody) or can include only an antigen-binding fragment (e.g., a 20 Fab, F(ab')<sub>2</sub>, Fv or a single chain Fv fragment). These include monoclonal antibodies, recombinant antibodies, chimeric antibodies, humanized antibodies, deimmunized antibodies, as well as antigen-binding fragments of the foregoing.

Antibodies (e.g., monoclonal antibodies from differing organisms, e.g., rodent, sheep, 25 human) can be produced using art-recognized methods. Once the antibodies are obtained, the variable regions can be sequenced. The location of the CDRs and framework residues can be determined (see, Kabat, E.A., et al. (1991) *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) *J. Mol. Biol.* 196:901-917). The light and heavy chain variable regions can, optionally, be ligated to corresponding constant regions. A light and the heavy immunoglobulin chains can be generated and co-expressed into the appropriate host cells.

30 Monoclonal anti-TLR4 antibodies can be used in the methods described herein. Suitable monoclonal antibodies can be generated using techniques known in the art. Monoclonal

antibodies can be produced by a variety of techniques, including conventional monoclonal antibody methodology, e.g., the somatic cell hybridization technique of Kohler and Milstein, *Nature* 256: 495 (1975). See generally, Harlow, E. and Lane, D. (1999) *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Although 5 somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibody can be employed e.g., viral or oncogenic transformation of B lymphocytes. A typical animal system for preparing hybridomas is the murine system. Hybridoma production in the mouse is a well-established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine 10 myeloma cells) and fusion procedures are also known.

Useful immunogens for the purpose of this invention include peptides comprising portions of TLR4 that are unique to TLR4. Human monoclonal antibodies (mAbs) directed against human proteins can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice 15 immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. International Application WO 92/03918; Kay et al. International Application 92/03917; Lonberg et al. 1994 *Nature* 368:856-859; Green, L.L. et al. 1994 *Nature Genet.* 7:13-21; Morrison, S.L. et 20 al. 1994 *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. 1993 *Year Immunol.* 7:33-40; Tuillion et al. 1993 *PNAS* 90:3720-3724; Bruggeman et al. 1991 *Eur. J. Immunol.* 21:1323-1326).

25 TRL4 antibodies are also commercially available, e.g., from Santa Cruz Biotechnology, Inc., Santa Cruz, CA. Monoclonal antibody MTS5510, available from Caltag Laboratories, Burlingame, CA, is known to act as a TLR4 antagonist and can be used as such within the methods described herein.

Dominant Negatives: The test compound can also be a dominant negative form of TLR4, e.g., a peptide or polypeptide that has a mutation that adversely affects, e.g., reduces the activity of the wild-type TLR4, typically by physically combining (i.e., dimerizing) with it. For example, 30 such dominant negative forms of TLR4 can be a truncated fragment of TLR4, e.g., a dominant negative fragment, or a missense mutation that results in dominant negative activity, e.g., as

described in Faure et al., *J. Biol. Chem.* 275(15)11058-11063 (2000), which describes both a fragment of TLR4 that is missing the 155 C-terminal amino acids of the wild-type TLR4, and a single amino acid (P712H) mutant, both of which function as dominant negative mutants (see also, Vogel et al., *J Immunol.* 1999 May 15;162(10):5666-70. Methods of making other such 5 mutants are known in the art, and one of skill in the art would be able to design and test such a dominant negative mutant. For example, TLR4 molecules with mutations in or deletions in a domain that interacts with a TLR4 binding partner, i.e., Tollip, MyD88, TIRAP/MAL, MD-2, CD14, and/or IRAK, may be used as dominant negatives.

#### Libraries

10 The test compound can be a molecule in a library, e.g., a library of compounds of related or unrelated structures. Such libraries are known in the art and are commercially available or can be synthesized.

15 Libraries of test compounds, such as small molecules, are available, e.g., commercially available, or can be synthesized using methods known in the art. As used herein, "small molecules" refers to small organic or inorganic molecules. In some embodiments, small molecules useful for the invention have a molecular weight of less than 3,000 Daltons (Da). The compounds can include organic or inorganic naturally occurring or synthetic molecules including but not limited to soluble biomolecules such as oligonucleotides, polypeptides, polysaccharides, 20 antibodies, fatty acids, etc.

20 The compounds can be natural products or members of a combinatorial chemistry library. A set of diverse molecules should be used to cover a variety of functions such as charge, aromaticity, hydrogen bonding, flexibility, size, length of side chain, hydrophobicity, and rigidity. Combinatorial techniques suitable for synthesizing small molecule compounds are known in the art, e.g., as exemplified by Obrecht, D. and Villalgrodo, J.M., *Solid-Supported Combinatorial 25 and Parallel Synthesis of Small-Molecular-Weight Compound Libraries*, Pergamon-Elsevier Science Limited (1998), and include those such as the "split and pool" or "parallel" synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, A.W., *Curr. Opin. Chem. Bio.*, (1997) 1, 60). In addition, a number of compound, e.g., small molecule, libraries are commercially available.

30 Libraries and test compounds screened using the methods of the present invention can comprise a variety of types of compounds. A given library, for example, can comprise a set of

structurally related or unrelated test compounds. In some embodiments, the compounds and libraries thereof can be obtained by systematically altering the structure of a first compound, e.g., a small molecule, e.g., a small molecule that is structurally similar to a known natural binding partner of TLR4 protein, or a fragment of the binding partner, or a small molecule identified as capable of binding the TLR4 protein, e.g., using methods known in the art or the methods described herein, and correlating that structure to a resulting biological activity, e.g., a structure-activity relationship study. As one of skill in the art will appreciate, there are a variety of standard methods for creating such a structure-activity relationship. Thus, in some instances, the work may be largely empirical, and in others, the three-dimensional structure of an endogenous polypeptide or portion thereof can be used as a starting point for the rational design of a test compound or compounds, e.g., a small molecule. For example, in one embodiment, a general library of small molecules is screened using the methods described herein.

#### Optimization

Compounds identified as "hits" (e.g., compounds that decrease TLR4 activity) in the first screen can be selected and systematically altered, e.g., using rational design, to optimize binding affinity, avidity, specificity, or other parameter. Such optimization can also be screened for using the methods described herein. Thus, in one embodiment, the invention includes screening a first library of compounds using the methods described herein, identifying one or more hits in that library, subjecting those hits to systematic structural alteration to create additional libraries of compounds structurally related to the hit, and screening the second library using the methods described herein.

#### Assays

The effect of the test compound on the activity of the TLR4 receptor can be measured using any assay known in the art. For example, the effect can be evaluated by measuring one or more of the following parameters:

(a) an effect on the level (number) of TLR4 proteins can be evaluated; e.g., by evaluating the transcription of TLR4 mRNA or the half-life of TLR4 mRNA (e.g., using a Northern blotting-based method, with or without a pulse-chase protocol to label the mRNA), or by evaluating the translation or half-life of the TLR4 protein (e.g., using a Western blotting-based method, with or without a pulse-chase protocol to label the protein), or by evaluating trafficking

or cellular localization of TLR4 protein (e.g., using an imaging-based microscopy method with labeled proteins or antibodies thereto);

(b) an effect on the binding of TLR4 to a TLR4 binding partner, i.e., Tollip, MyD88, TIRAP/MAL, MD-2, CD14, and/or IRAK (e.g., using known binding assays); and/or

5 (c) an effect on the activity of TLR4 protein by altering one or more post-translational modifications (e.g., using known assays for post-translational modifications including but not limited to glycosylation and phosphorylation).

The assay can be a high throughput assay, e.g., a high throughput assay evaluating a parameter described herein. A number of such assays, and methods for developing them, are  
10 known in the art.

In some embodiments, the method includes evaluating the effect of a test compound on one of these parameters in a first assay, selecting the "hits" from the first assay, and evaluating the test compound in a model system. For example, the model system can be an animal model of pancreatitis, and the effect of the compound can be an improvement in a clinical parameter, e.g.,  
15 the clinical course of the pancreatitis (e.g., onset (i.e., delayed onset), severity (i.e., decreased severity), duration (i.e., decreased duration) and/or recurrence (i.e., decreased recurrence) of the pancreatitis). In some embodiments, the clinical parameter is evaluated in the pancreas of a model animal by measuring MPO activity, serum amylase levels, percent necrosis, or percent edema.

20 In some embodiments, the method includes providing a test compound that is known or suspected to have an effect on TLR4 activity (e.g., known to decrease TLR4 activity), and evaluating the candidate compound in a model system as described herein.

25 The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

## EXAMPLES

### Example 1: Caerulein Fails to Induce Acute Pancreatitis in TLR4 Knockout Mice

*Materials.* Animals were generated as previously described (Hoshino et al., J. Immunol. 1999 162:3749-1752). Caerulein, a decapeptide analogue of the potent pancreatic secretagogue cholecystokinin, was purchased from Peptide International. All other chemicals and reagents

were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA) and Diagnostic chemicals limited (Charlottetown Canada).

*Animal Model of Pancreatitis.* Studies were performed on wild type and TLR4-/- transgenic mice weighing about 25-30 grams. Animals were housed in cages under standard conditions at room temperature with a twelve-hour light and dark cycle. Food and drinking water were available ad libitum. Secretagogue-induced pancreatitis was elicited by the hourly (twelve times) intraperitoneal injection of caerulein (50 µg/kg). Caerulein is a specific decapeptide obtained from the skin of *Hyla caerulea*, and Australian amphibian. Similar in action to cholecystokinin, caerulein stimulates gastric, biliary, and pancreatic secretion and certain smooth muscle. Clinically, caerulein is used in paralytic ileus, and as an aid in the diagnosis of pancreatic malfunction. Control animals received a comparable amount of saline. One hour after the final caerulein or saline injection, animals were sacrificed by CO<sub>2</sub> asphyxia, and tissue and blood samples were rapidly prepared for study. Harvested blood was allowed to clot and then centrifuged, and serum was obtained for measurement of amylase. The pancreas was rapidly removed and fixed in 10% neutral phosphate-buffered formalin for histological study. Other samples of pancreas were prepared for measurement of tissue myeloperoxidase (MPO) activity by snap freezing in liquid nitrogen.

*Evaluation of Pancreatitis Severity.* Tissue myeloperoxidase (MPO) activity was used as a marker for the sequestration of neutrophils within the pancreas by quantitating photometrically using 3,3',5,5'-tetramethylbenzidine as a substrate. Pancreatic edema was quantitated by measuring tissue water content and expressing it as a percentage of tissue wet weight. Serum amylase activity was quantitated as described in Singh et al., *J. Clin. Invest.* 2001, 108:1387-1395. The extent of pancreatic acinar cell necrosis was quantitated morphometrically by an observer who was not aware of the sample identity. For these studies, paraffin-embedded samples were sectioned (5 µm) and stained with hematoxylin and eosin. Ten randomly chosen microscopic fields (x125) were examined for each tissue sample, and the extent of acinar cell injury/necrosis was expressed as a percentage of total acinar tissue.

*Analysis of data.* The results reported represent mean plus or minus SE of mean values for multiple determinations from eight to ten animals (*in vivo* studies). The significance of changes was evaluated using student's t test when comparing two groups and ANOVA when comparing three or more groups. P values of less than 0.05 were considered to be significant.

*Measurement of pancreas water content.* Fragments of pancreas were blotted dry and weighed to determine tissue wet weight. They were then desiccated by overnight incubation at 140°C and reweighed to determine tissue dry weight. Tissue water content was calculated as the difference between wet and dry weight and expressed as a percentage of wet weight.

5 *Morphological Examination.* Paraffin-embedded pancreas samples were sectioned (5  $\mu$ m), stained with hematoxylin/eosin, and examined by an experienced morphologist who was not aware of the sample identity. Acinar-cell injury/necrosis was quantitated by morphometry as described. For these studies, 10 randomly chosen microscopic fields ( $\times 125$ ) were examined for each tissue sample and the extent of acinar-cell injury/necrosis was expressed as the percent of 10 the total acinar tissue that was occupied by areas meeting the criteria for injury/necrosis. Those criteria were defined as vacuolization and swelling of acinar cells and the destruction of the histoarchitecture of whole or parts of the acini, both of which had to be associated with an inflammatory reaction. Lung tissues can be evaluated using similar methodology.

15 *Serum Amylase Activity and MPO Assays.* Serum amylase activity was measured with  $\alpha$ -amylase (Diagnostic Chemicals Limited, Canada) as a substrate on Cobas FARA Autoanalyzer. Neutrophil sequestration in the pancreas was quantitated by measuring tissue MPO activity. For these measurements, tissue samples harvested at the time of sacrifice were stored at -70°C. They were thawed, homogenized with Teflon homogenizer in 1 ml of 50 mM phosphate buffer (pH 7.4), centrifuged (14,000  $\times$  g, 15 min, 4°C) and the resulting pellet was resuspended in 50 mM 20 phosphate buffer (pH 7.4) and centrifuged (14,000  $\times$  g, 15 min, 4°C) again.

25 The pellet thus obtained was resuspended in 50 mM phosphate buffer 50 mM (pH 6.0) containing 0.5% hexadecyltrimethylammonium bromide (Sigma) and homogenized with polytron homogenizer. The suspension was subjected to one cycle of freeze (-80°C) and thaw (37°C) and further disrupted by sonication (40 sec). The sample was then centrifuged (14,000  $\times$  g, 15 min, 37°C) and the supernatant were used for the MPO assay. The reaction mixture consisted of this extracted enzyme, 20 mM tetramethylbenzidine (Sigma), 100 mM sodium phosphate buffer (pH 5.4), 0.5% hexadecyltrimethylammonium bromide (Sigma) and 0.03% hydrogen peroxide. This mixture was incubated at 37°C for 200 seconds and the increase in absorbance at 655 nm was measured in a Cobas FARA autoanalyzer.

30 *Results.* Wild-type mice given i.p. injections of a supramaximally stimulating dose of the secretagogue caerulein develop acute edematous pancreatitis. This is manifested by a rise in

serum amylase activity, pancreatic MPO activity (an indicator of neutrophils sequestration in the pancreas), and morphological evidence of extensive acinar cell necrosis. In contrast, caerulein administration to TLR4-/- mice resulted in significantly less severe pancreatitis.

As can be seen in Fig. 1, serum amylase activity was reduced more than 1.6 fold in  
5 TLR4-/- mice as compared to wild type mice. In addition, MPO activity was significantly reduced from  $363.30 \pm 58.54$  in wild type to  $88.00 \pm 9.75$  in TLR4-/- mice pancreas (Fig. 2). Similarly, pancreatic water content was reduced from  $83.30 \pm 0.41$  in wild type to  $79.56 \pm 0.43$  in  
10 TLR4-/- mice after 12 caerulein i/p injections (Fig. 3). Acinar cell necrosis in the pancreas of TLR4-/- mice (as shown in fig. 4) after caerulein administration for 12 hours was significantly reduced to  $6.83 \pm 0.98$  as compared to  $17.38 \pm 1.50$  in wild type mice.

*Histology of secretagogue-induced pancreatitis.* Marked inflammation and acinar cell necrosis, clearly apparent in the caerulein treated wild type mouse pancreas (Fig. 6; compare to untreated control mouse, Fig. 5), is decreased in the TLR4-/- mouse pancreatic tissue (Fig. 8; compare to untreated control knockout mouse, Fig. 7).

15 These results indicate that TLR4 plays a role in the development of pancreatitis.

#### OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the  
20 scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. 1. A method of identifying a candidate therapeutic agent for use in the treatment of acute  
2. pancreatitis, the method comprising:
  3. providing a cell expressing a TLR4 protein;
  4. contacting the cell with a test compound; and
  5. evaluating an effect of the test compound on the activity of the TLR4 protein,  
6. wherein a test compound that reduces the activity of the TLR4 protein is a candidate  
7. therapeutic agent for use in the treatment of acute pancreatitis.
8. 2. The method of claim 1, wherein the test compound reduces the activity of the TLR4  
9. protein by reducing the level (number) of TLR4 proteins.
10. 3. The method of claim 2, wherein the test compound reduces the level (number) of TLR4  
11. proteins by reducing the transcription of TLR4 mRNA or the half-life of TLR4 mRNA.
12. 4. The method of claim 2, wherein the test compound reduces the level (number) of TLR4  
13. proteins by reducing the translation of TLR4 protein, trafficking of TLR4 protein, half-  
14. life of TLR4 protein, or cellular localization of TLR4 protein.
15. 5. The method of claim 1, wherein the test compound reduces the activity of the TLR4  
16. protein by interfering with binding of TLR4 to a TLR4 binding partner.
17. 6. The method of claim 5, wherein the TLR4 binding partner is selected from the group  
18. consisting of Tollip, MyD88, TIRAP/MAL, MD-2, CD14, and IRAK.
19. 7. The method of claim 1, wherein the test compound reduces the activity of the TLR4  
20. protein by altering one or more post-translational modifications.
21. 8. The method of claim 1, wherein the test compound is an siRNA, antisense nucleic acid,  
22. ribozyme, or TLR4 specific antibody.
23. 9. The method of claim 1, further comprising:
  24. selecting a test compound identified by the method of claim 1 as a candidate  
25. therapeutic agent;
  26. providing a model system for acute pancreatitis;
  27. contacting the model system with the test compound; and
  28. evaluating a clinical parameter relating to the acute pancreatitis in the model  
29. system in the presence and the absence of the test compound,

30 wherein an improvement in the clinical parameter indicates that the test compound is a  
31 candidate therapeutic agent for use in the treatment of acute pancreatitis.

32 10. A method of identifying a candidate therapeutic agent for use in the treatment of acute  
33 pancreatitis, the method comprising:

34 providing a test compound that is known or suspected to decrease TLR4 activity;

35 providing a model system for acute pancreatitis;

36 contacting the model system with the test compound; and

37 evaluating a clinical parameter relating to the acute pancreatitis in the model

38 system in the presence and the absence of the test compound,

39 wherein an improvement in the clinical parameter indicates that the test compound is a  
40 candidate therapeutic agent for use in the treatment of acute pancreatitis.

41 11. The method of claim 9 or 10, wherein the model system is an animal model of acute  
42 pancreatitis.

43 12. The method of claim 9 or 10, wherein the model system is a patient diagnosed with acute  
44 pancreatitis.

45 13. The method of claim 9 or 10, wherein the parameter relating to the acute pancreatitis is  
46 time of onset, severity, duration, or recurrence.

47 14. The method of claim 11, wherein the parameter is measured by measuring MPO activity,  
48 serum amylase levels, percent necrosis, or percent edema in the pancreas of the animal  
49 model.

50 15. A method of treating a patient having acute pancreatitis, the method comprising  
51 administering to the patient a therapeutically effective amount of a candidate therapeutic  
52 agent identified by a method according to claim 1, 9, or 10.

53 16. The method of claim 16, wherein the patient also has a pancreatitis-associated disorder  
54 selected from the group consisting of lung injury, kidney failure, and heart failure.

## **ABSTRACT**

The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.

20753479.doc




FIG. 1




FIG. 2






FIG. 3




\*\* p Value < .01 W/T vs TLR4 K/O

FIG. 4

Title: Pancreatitis  
Inventor: Saluja  
Attorney Docket No: 07917-251P01  
Page 3 of 4




**FIG. 5**




**FIG. 6**

Title: Pancreatitis  
Inventor: Saluja  
Attorney Docket No: 07917-251P01  
Page 4 of 4



**FIG. 7**



**FIG. 8**

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/038950

International filing date: 19 November 2004 (19.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/523,942

Filing date: 21 November 2003 (21.11.2003)

Date of receipt at the International Bureau: 10 January 2005 (10.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**